Federal University of Mato Grosso do Sul   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Campo Grande Brazil (1979)

Organization Overview

First Clinical Trial
2010
NCT01354249
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Instituto de Cardiologia/ Fundação Universitária de Cardiologia | Julio Muller University Hospital Federal University of Mato Grosso

Active Ingredients

Drugs in Phase 4 Trials (1)

isoniazid (nydrazid) (1 trial)

Drugs in Phase 3 Trials (4)

icosapent ethyl (vascepa) (1 trial)

maltodextrin (2 trials)

meglumine antimoniate (1 trial)

miltefosine (impavido) (1 trial)

Drugs in Phase 2 Trials (1)

l-glutamine (1 trial)

Drugs in Other Trials (1)

whey protein (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrial Fibrillation (Phase 3)

Leishmaniasis (Phase 3)

Leishmaniasis, Cutaneous (Phase 3)

Postoperative Complications (Phase 3)

Proctitis (Phase 3)

Respiratory Aspiration of Gastric Contents (Phase 2)

Tuberculosis (Phase 4)

Tuberculosis, Pulmonary (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial APIs: 7